A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2‐year efficacy and safety of nilotinib and their relationship...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Med
Main Authors: Shin, Junghoon, Koh, Youngil, Yoon, Seo Hyun, Cho, Joo‐Youn, Kim, Dae‐Young, Lee, Kyoo‐Hyung, Kim, Hyeong‐Joon, Ahn, Jae‐Sook, Kim, Yeo‐Kyeoung, Park, Jinny, Sohn, Sang‐Kyun, Moon, Joon Ho, Lee, Yoo Jin, Yoon, Seonghae, Lee, Jeong‐Ok, Cheong, June‐Won, Kim, Kyoung Ha, Kim, Sung‐Hyun, Kim, Hoon‐Gu, Kim, Hawk, Nam, Seung‐Hyun, Do, Young Rok, Park, Sang‐Gon, Park, Seong Kyu, Bae, Sung Hwa, Song, Hun Ho, Shin, Dong‐Yeop, Oh, Doyeun, Kim, Min Kyoung, Jung, Chul Won, Park, Seonyang, Kim, Inho
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Clinical Cancer Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5943463/
https://ncbi.nlm.nih.gov/pubmed/29577674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1450
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items